Equibles does not estimate personal net worth.
Get an email with a short summary when Milestone Scientific Inc. publishes a filing, an earnings call transcript or a press release.
Get MLSS alertsArjan Haverhals is recorded as Board Member at Milestone Scientific Inc. (MLSS) since January 4, 2023. Milestone Scientific Inc. reported in an 8-K filed November 14, 2024 that Arjan Haverhals retired as Chief Executive Officer, effective December 31, 2024. Milestone Scientific Inc. reported in an 8-K filed January 5, 2023 that Arjan Haverhals was appointed director, effective January 4, 2023. Arjan Haverhals has spoken on 17 earnings calls across 1 company, most recently for Milestone Scientific Inc. on September 30, 2024. Milestone Scientific Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Milestone Scientific Inc. includes Jan Adriaan (Arjan) Haverhals (CEO), Leonard Osser (CEO), Neal Goldman (CEO, Chairman and Board Member) and 7 others.
“On November 8, 2024, Mr. Arjan Haverhals, the Chief Executive Officer of Milestone Scientific Inc. (the "Company"), advised the Chairman of the Board that he intends to retire as an officer from the Company upon the expiration of, and not seek the renewal of, his employment agreement, on December 31, 2024.”
“Also on January 4, 2023, the Board unanimously appointed Arjan Haverhals as a director of the Company.”
“And thanks to everyone joining us on the call today. This quarter was an important one for Milestone Scientific as we achieved a 22% increase in year-over-year revenue, reaching $2.5 million, primarily driven by strong growth in our dental division.”
“This has been a momentous year for the company, as we recently achieved a major milestone with the grant of Medicare Part B physician payment rate assignment for our CompuFlo epidural system.”
“We achieved revenue of more than $2.2 million for the first quarter of 2024. Although our revenue was down slightly compared to the same period last year, this was largely a reflection of a reserve reversal in the first quarter of 2023, coupled with a decline in international sales during the first quarter of 2024.”
“I'm pleased to report that we achieved solid financial results in 2023 with revenue increasing 12% to $9.8 million. We also reported an increase in gross profit of 39% for the full year 2023 to $6.8 million.”
“We achieved revenues of $2.1 million for the third quarter of 2023. However, these results do not reflect the true underlying improvements in the business.”
2023-01-04–present
Proxy statement
Start not stated–present
Last confirmed April 30, 2021
Start not stated–2024-12-31
Medical Instruments & Supplies · Healthcare
Board Member
2023-01-04–present
